Literature DB >> 1700791

A conformation-dependent epitope of human platelet glycoprotein IIIa.

W C Kouns1, C D Wall, M M White, C F Fox, L K Jennings.   

Abstract

This study explores conformational states of human platelet glycoprotein IIIa (GP IIIa) and possible mechanisms of fibrinogen receptor exposure. D3GP3 is an IgG1, kappa monoclonal antibody generated against purified GP IIIa and found to be specific for GP IIIa by immunoprecipitation and Western blot analysis. The binding of D3GP3 to resting platelets caused fibrinogen binding (approximately 5,000 molecules/platelet) and platelet aggregation but not secretion. Platelets express 40,000-50,000 GP IIb-IIIa molecules in their surface membranes. However, resting platelets only bound approximately 5,000 D3GP3 molecules/platelet. D3GP3 binding to platelets could be increased 2-3-fold by dissociation of the GP IIb-IIIa complex with 5 mM EDTA or by occupying the fibrinogen receptor with either RGDS peptides or fibrinogen. Platelet stimulation with ADP in the absence of fibrinogen did not cause increased D3GP3 binding above control levels. These data suggest that 1) GP IIb-IIIa can exist in multiple conformations in the platelet membrane, 2) D3GP3 binding to GP IIIa can expose the fibrinogen receptor, 3) the binding of either RGDS peptides or fibrinogen causes exposure of the D3GP3 epitope, and 4) platelet activation in the absence of ligand does not induce the same conformational changes in GP IIb-IIIa as does receptor occupancy by RGDS peptides or fibrinogen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700791

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Effects of limiting extension at the alphaIIb genu on ligand binding to integrin alphaIIbbeta3.

Authors:  Robert Blue; Jihong Li; Jonathan Steinberger; Marta Murcia; Marta Filizola; Barry S Coller
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

2.  The beta3 subunit of the integrin alphaIIbbeta3 regulates alphaIIb-mediated outside-in signaling.

Authors:  Junling Liu; Carl W Jackson; Ralph A Gruppo; Lisa K Jennings; T Kent Gartner
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

3.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

4.  Ligand density dramatically affects integrin alpha IIb beta 3-mediated platelet signaling and spreading.

Authors:  Markéta Jirousková; Jyoti K Jaiswal; Barry S Coller
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

5.  Tests of the extension and deadbolt models of integrin activation.

Authors:  Jieqing Zhu; Brian Boylan; Bing-Hao Luo; Peter J Newman; Timothy A Springer
Journal:  J Biol Chem       Date:  2007-02-13       Impact factor: 5.157

6.  Requirement of alpha and beta subunit transmembrane helix separation for integrin outside-in signaling.

Authors:  Jieqing Zhu; Christopher V Carman; Minsoo Kim; Motomu Shimaoka; Timothy A Springer; Bing-Hao Luo
Journal:  Blood       Date:  2007-07-05       Impact factor: 22.113

7.  Rationally designed integrin beta3 mutants stabilized in the high affinity conformation.

Authors:  Bing-Hao Luo; John Karanicolas; Laura D Harmacek; David Baker; Timothy A Springer
Journal:  J Biol Chem       Date:  2008-11-19       Impact factor: 5.157

8.  Glycoprotein IIb-IIIa and the translocation of Rap2B to the platelet cytoskeleton.

Authors:  M Torti; G Ramaschi; F Sinigaglia; E G Lapetina; C Balduini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  Mechanisms of platelet activation by a stimulatory antibody: cross-linking of a novel platelet receptor for monoclonal antibody F11 with the Fc gamma RII receptor.

Authors:  U P Naik; Y H Ehrlich; E Kornecki
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

Review 10.  Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.

Authors:  Ian C Gilchrist
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.